Abstract 1629P
Background
The management of pancreatic adenocarcinoma continues to be challenging. Surgical resection is the only modality for a cure, with an overall survival rate of 10–20% at 5 years. However, only 20% of the patients are surgical candidates because of locally advanced disease or systemic stage at presentation.
Methods
A phase II clinical trial was carried out on 50 patients with previously untreated locally advanced, surgically unresectable pancreatic adenocarcinoma. Patients had ECOG PS 0 or 1 and adequate hematologic, renal, and hepatic function. They arranged to receive 3 cycles of modified FOLFIRINOX prior to CCRT, with losartan taken orally every day followed by chemoradiotherapy.
Results
Response after completion CCRT was assessed. 6% of patients achieved complete response. 38% of the patients had a partial response, while twenty-four patients (48%) had stable disease and 8% had progressive disease. Of the 50 patients, thirteen (26%) underwent surgery, with R0 resection achieved in 6 of 13 patients. Median follow-up period was 20.25 months (range, 6.0-34.5). The median PFS was 12 months (95% CI, 9.647 – 14.353), while Median OS was 21 months (95% CI, (10.200–31.800). The patients who underwent resection had longer survival 24 months (95% CI, (16.363 – 27.637) compared to those who did not undergo resection; mean OS was 14 months (95% CI, (9.205 – 18.795)). (P=0.271). The patients who achieved CR after modified Folforinox-losartan had a longer median OS of 33 months (95% CI, 19.918 – 46.082) compared to patients who had PR and SD, each had median OS of 13 months (95% CI, 6.768 – 19.232), (11.718 – 14.282) respectively (P=0.040*). The patients who achieved CR after CCRT had longer OS (NR) compared to those who had PR, SD and PD. median OS was 24, 14 and 8 months, respectively (95% CI, 6.761 – 41.239), (11.022 – 16.978), and (95% CI, 4.080 – 11.920) (P=<0.001*). The patients who achieved CR after CCRT had longer PFS (NR) compared to those who had PR, SD and PD. Median PFS was 24 (95% CI, 13.191 – 34.809), 10(95% CI, 4.973 – 15.027) and 5 (95% CI,4.823-5.124) months, respectively (P=<0.001*).
Conclusions
Induction chemotherapy with modified-FOLFIRINOX-losartan, followed by CCRT improved patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22
1644P - The mutation landscape and evolution pattern of liver or peritoneal metastasis in pancreatic cancer
Presenter: Guoliang Yao
Session: Poster session 22